professionalIMG

Scott A. Samuels

Member vCard
Boston
617.348.1798



Education

  • George Mason University (JD, 1996)
  • Cornell University (BA, 1992)

Bar Admissions

  • Massachusetts
  • Pennsylvania

Scott’s practice focuses on corporate and securities law matters, primarily for life sciences and technology companies. Scott has represented public and private companies, underwriters, venture capital funds, angel investors, and other parties in a broad range of transactions, including initial and follow-on public offerings, mergers and acquisitions, and equity and debt financings.

Scott also devotes a significant portion of his practice to counseling public companies with respect to SEC disclosure, compliance, and corporate governance matters, including Sarbanes-Oxley, Dodd-Frank, the JOBS Act, and SEC and stock exchange regulations. Scott also advises earlier stage companies on general corporate matters, including formation, financing, and employee/consultant agreements.

Before joining Mintz Levin, Scott served as a law clerk for a federal judge in the US District Court, Eastern District of Pennsylvania. During law school, he interned for the Chairman of the Federal Communications Commission and in the Antitrust Division of the US Department of Justice, and he was editor-in-chief of the George Mason Law Review.

Representative Matters


Public & Private Offerings for Public Companies

  • Represented Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) in its $86 million initial public offering
  • Represented ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) in its $258 million follow-on public offering and other public offerings
  • Represented BG Medicine, Inc. (Nasdaq: BGMD) in its $40 million initial public offering
  • Represented Synta Pharmaceuticals Corp. (Nasdaq: SNTA) in its $35 million equity line facility with Azimuth Opportunity Ltd.
  • Represented Alphatec Holdings, Inc. (Nasdaq: ATEC) in its $92 million follow-on and secondary public offering
  • Represented Azure Dynamics Corporation (TSX: AZD) in various US private placements conducted contemporaneously with Canadian public offerings
  • Represented Archemix Corp. (Nasdaq: withdrawn) in its proposed initial public offering
  • Represented Myriad Genetics, Inc. (Nasdaq: MYGN) in its $105 million follow-on public offering and other public offerings
  • Represented King Pharmaceuticals, Inc. (NYSE: KG) in a Rule 144A offering and resale registration of $400 million convertible debentures
  • Represented Altus Pharmaceuticals Inc. (Nasdaq: ALTU) in its $110 million initial public offering
  • Represented Manulife Financial Corporation and John Hancock Variable Life Insurance Company (NYSE: MFC) in an $80 million offering of guaranteed variable annuities

Mergers & Acquisitions

  • Represented Boston Biomedical, Inc. in its up to $2.6 billion acquisition by Dainippon Sumitomo Pharma Co., Ltd. (Tokyo Stock Exchange)
  • Represented Pluromed, Inc. in its acquisition by Sanofi (NYSE: SNY) (undisclosed amount)
  • Represented Myriad Genetics, Inc. (Nasdaq: MYGN) in its $25 million strategic debt investment and option to acquire Crescendo Bioscience, Inc.
  • Represented Myriad Genetics, Inc. (Nasdaq: MYGN) in its $80 million acquisition of Rules-Based Medicine, Inc.
  • Represented FoldRx Pharmaceuticals, Inc. in its acquisition by Pfizer, Inc. (NYSE: PFE) (undisclosed amount)
  • Represented ION Torrent Systems Incorporated in its $725 million acquisition by Life Technologies Corporation (Nasdaq: LIFE)
  • Represented Alphatec Holdings, Inc. (Nasdaq: ATEC) in its acquisition of Scient’x Groupe SAS (all stock consideration)
  • Represented Myriad Genetics, Inc. (Nasdaq: MYGN) in its spin-off of Myriad Pharmaceuticals, Inc. into a separately traded public company, now named Myrexis, Inc. (Nasdaq: MYRX)
  • Represented Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in its $300+ million (cash and stock) acquisition of ViroChem Pharma Inc.
  • Represented Archemix Corp. in its proposed reverse merger with Nitromed, Inc. (Nasdaq: NTMD) (terminated)
  • Represented ClariFI, Inc. in its acquisition by Standard & Poor’s, a division of the Mc-Graw Hill Companies (NYSE: MHP) (undisclosed amount)
  • Represented Netonomy, Inc. in its $19 million acquisition by Comverse Technology, Inc. (Nasdaq: CMVT)
  • Represented the MacGregor Group, Inc. in its $230 million acquisition by Investment Technology Group, Inc. (NYSE: ITG)
  • Represented Connected Corporation in its $117 million acquisition by Iron Mountain Incorporated (NYSE: IRM)

Venture Capital & Other Financings

  • Represented Angiochem, Inc. in its license transaction with Geron Corporation (Nasdaq: GERN), including the private placement by Geron of $27.5 million of shares of common stock.
  • Represented Archemix Corp. in its Series B, C, and D financings and in general corporate matters
  • Represented TwistDx, Inc., Genetix Pharmaceuticals, Inc., Performance Plants, Inc., Senex Biotechnology, Inc. and other private companies in various equity and convertible debt financings
  • Represented MPM Capital and other investors in a $45 million Series A financing of Alinea Pharmaceuticals, Inc.
  • Represented Aureon Laboratories, Inc. in its $20 million Series B financing

Recognitions & Awards

  • Recommended by The Legal 500 United States for Healthcare: Life Sciences (2013)
  • Massachusetts Super Lawyers: Rising Star – Securities & Corporate Finance (2005 – 2007)